Clinical catalysts
The strategy selects near-term clinical events expected to significantly alter equity valuations. Long or short positions follow a deep scientific assessment of each event.
- Strategy
- +15.5%
- S&P 500
- +0.2%
- XBI
- −1.4%
For investors
Investment strategies built for biotech.
Mean reversion
The strategy screens for double-digit drops that are not explained by material corporate events. Signals are then filtered to companies with a positive long-term outlook.
- Strategy
- +23.4%
- S&P 500
- +6.7%
- XBI
- +21.7%
Past performance is not indicative of future results. The information exhibited here does not represent investment advice.